Efficacy and safety of tofacitinib in the treatment of refractory cases of polyarticular course juvenile idiopathic arthritis: A study from Bangladesh
| العنوان: | Efficacy and safety of tofacitinib in the treatment of refractory cases of polyarticular course juvenile idiopathic arthritis: A study from Bangladesh |
|---|---|
| المؤلفون: | Mohammad Masudur Rahman, Kamrul Laila, Shahana Akhter Rahman |
| المصدر: | International Journal of Rheumatic Diseases. 25:678-684 |
| بيانات النشر: | Wiley, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Bangladesh, Pyrimidines, Treatment Outcome, Piperidines, Rheumatology, Antirheumatic Agents, Humans, Child, Arthritis, Juvenile |
| الوصف: | Biological disease-modifying antirheumatic drugs (bDMARDs) are treatment options for refractory juvenile idiopathic arthritis (JIA) cases which cannot be afforded by the majority. Tofacitinib is a novel Janus kinase inhibitor, which is reported to be a cost-effective oral alternative to biologics. This prospective observational study was carried out to observe the efficacy and safety of tofacitinib in refractory polyarticular course JIA patients.The study was conducted in the Department of Pediatrics, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka. Twenty-seven refractory polyarticular course JIA patients were included in this study. Patients received tofacitinib at recommended doses. Disease activity level was assessed by Juvenile Arthritis Disease Activity Score (JADAS) 27. Cases were evaluated at baseline and at the 6th, 12th and 24th weeks. Safety was monitored from history, examination findings and laboratory reports. Data were analyzed using appropriate statistical tests.Enthesitis-related arthritis was the commonest type (37%) followed by polyarticular (rheumatoid factor+) and systemic JIA. There was significant improvement in JADAS 27 in all the subtypes of JIA except oligoarticular extended type. Among 100% high disease activity state cases at baseline, 70.4% were inactive at 24 weeks. It was also possible to significantly reduce the dose of steroid. Few side effects like headache and vomiting, elevation of alanine aminotransferase and anemia were observed at 6 weeks. These side effects subsequently improved.Significant reduction of disease activity score was observed from baseline to follow up in this study. Tofacitinib was well tolerated with minimum side effects. |
| تدمد: | 1756-185X 1756-1841 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::853c5ce6134ce1d914ad057b0e5a7877Test https://doi.org/10.1111/1756-185x.14324Test |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....853c5ce6134ce1d914ad057b0e5a7877 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1756185X 17561841 |
|---|